Literature DB >> 1102178

Fetal haemoglobin in homozygous sickle cell disease.

G R Serjeant.   

Abstract

Synthesis of fetal haemoglobin is prolonged in homozygous sickle cell disease. Its intracellular distribution is irregular and red cells containing high levels of Hb F enjoy greater protection from sickling and subsequent destruction. This relationship is reflected in a number of associations between Hb F level and the haematological and clinical parameters of the disease. High fetal haemoglobin levels are associated with more normal red cell survival, more normal oxygen affinity, and more normal red cell characteristics whereas clinically they are associated with less evidence of vessel obstruction, persistence of splenomegaly, more normal skeletal development and body habitus, and a generally more benign clinical course. Attempts to prolong Hb F synthesis might therefore be expected to lead to amelioration of the clinical features of the disease. The factors leading to persistence of Hb F synthesis is SS disease are largely unknown although they appear to be operative as early as the first three months of life.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1102178

Source DB:  PubMed          Journal:  Clin Haematol        ISSN: 0308-2261


  20 in total

Review 1.  Hydroxyurea for children with sickle cell disease.

Authors:  Matthew M Heeney; Russell E Ware
Journal:  Hematol Oncol Clin North Am       Date:  2010-02       Impact factor: 3.722

2.  Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia.

Authors:  Mehdi Nouraie; Noel S Reading; Andrew Campbell; Caterina P Minniti; Sohail R Rana; Lori Luchtman-Jones; Gregory J Kato; Mark T Gladwin; Oswaldo L Castro; Josef T Prchal; Victor R Gordeuk
Journal:  Br J Haematol       Date:  2010-05-09       Impact factor: 6.998

3.  Sickle Cell Disease: Reappraisal of the Role of Foetal Haemoglobin Levels in the Frequency of Vaso-Occlusive Crisis.

Authors:  C Antwi-Boasiako; E Frimpong; G K Ababio; B Dzudzor; I Ekem; B Gyan; N A Sodzi-Tettey; D A Antwi
Journal:  Ghana Med J       Date:  2015-06

Review 4.  Hb F in sickle cell anemia.

Authors:  A D Adekile; T H Huisman
Journal:  Experientia       Date:  1993-01-15

5.  Alpha thalassemia changes erythrocyte heterogeneity in sickle cell disease.

Authors:  C T Noguchi; G J Dover; G P Rodgers; G R Serjeant; S E Antonarakis; N P Anagnou; D R Higgs; D J Weatherall; A N Schechter
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

6.  Common haplotype dependency of high G gamma-globin gene expression and high Hb F levels in beta-thalassemia and sickle cell anemia patients.

Authors:  D Labie; J Pagnier; C Lapoumeroulie; F Rouabhi; O Dunda-Belkhodja; P Chardin; C Beldjord; H Wajcman; M E Fabry; R L Nagel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

7.  G gamma beta+ hereditary persistence of fetal hemoglobin: cosmid cloning and identification of a specific mutation 5' to the G gamma gene.

Authors:  F S Collins; C J Stoeckert; G R Serjeant; B G Forget; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

8.  Blood rheology and proliferative retinopathy in sickle cell-haemoglobin C disease.

Authors:  B E Serjeant; K P Mason; P I Condon; R J Hayes; M W Kenny; J Stuart; G R Serjeant
Journal:  Br J Ophthalmol       Date:  1984-05       Impact factor: 4.638

Review 9.  Differences in the clinical and genotypic presentation of sickle cell disease around the world.

Authors:  Santosh L Saraf; Robert E Molokie; Mehdi Nouraie; Craig A Sable; Lori Luchtman-Jones; Gregory J Ensing; Andrew D Campbell; Sohail R Rana; Xiao M Niu; Roberto F Machado; Mark T Gladwin; Victor R Gordeuk
Journal:  Paediatr Respir Rev       Date:  2013-11-15       Impact factor: 2.726

10.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.

Authors:  Gregory J Kato; Robert P Hebbel; Martin H Steinberg; Mark T Gladwin
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.